NXTC vs. ALGS, GNTA, AVTE, EPIX, MGX, MURA, ENTX, ASRT, IMAB, and PYXS
Should you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Aligos Therapeutics (ALGS), Genenta Science (GNTA), Aerovate Therapeutics (AVTE), ESSA Pharma (EPIX), Metagenomi (MGX), Mural Oncology (MURA), Entera Bio (ENTX), Assertio (ASRT), I-Mab (IMAB), and Pyxis Oncology (PYXS). These companies are all part of the "pharmaceutical products" industry.
NextCure vs.
Aligos Therapeutics (NASDAQ:ALGS) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.
NextCure received 54 more outperform votes than Aligos Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Aligos Therapeutics an outperform vote while only 65.08% of users gave NextCure an outperform vote.
Aligos Therapeutics currently has a consensus price target of $70.00, suggesting a potential upside of 595.48%. NextCure has a consensus price target of $3.50, suggesting a potential upside of 566.67%. Given Aligos Therapeutics' higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than NextCure.
NextCure has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,283.19%. NextCure's return on equity of -62.50% beat Aligos Therapeutics' return on equity.
Aligos Therapeutics has a beta of 2.52, meaning that its stock price is 152% more volatile than the S&P 500. Comparatively, NextCure has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.
In the previous week, Aligos Therapeutics had 3 more articles in the media than NextCure. MarketBeat recorded 4 mentions for Aligos Therapeutics and 1 mentions for NextCure. NextCure's average media sentiment score of 1.89 beat Aligos Therapeutics' score of 0.90 indicating that NextCure is being referred to more favorably in the news media.
60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 8.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 13.3% of NextCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
NextCure has lower revenue, but higher earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.
Summary
NextCure beats Aligos Therapeutics on 10 of the 16 factors compared between the two stocks.
Get NextCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NextCure Competitors List
Related Companies and Tools
This page (NASDAQ:NXTC) was last updated on 3/26/2025 by MarketBeat.com Staff
